Search Follow us
Refine By

Stock Exchange

Market Cap (m)


Type of Publication


1 - 4 of 4
Sort by: popularity | newest
Page  of 1

FOLFIRINOX sets bar in pancreatic cancer high

Update | Pharmaceutical & healthcare | 13 Jun 2018

On 12 June, Targovax announced a strategic decision to move away from developing TG01, a neoantigen cancer vaccine for resected pancreatic cancer after new data with FOLFIRINOX set the bar for overall survival too high. With median overall survival of resected pancreatic cancer patients approaching five years, such a long clinical trial is beyond the capabilities of a relatively small biotech company, according to Targovax. We have removed pancreatic cancer from our valuation, which is now NOK1.31bn or NOK24.9/share (vs NOK33.8/share previously).


Key catalysts in 2018

Update | Pharmaceutical & healthcare | 16 Mar 2018

Q417 saw the release of several reports indicating a good safety profile and consistent immune activation signs by ONCOS-102, an oncolytic virus for melanoma and mesothelioma, and TG02, a neo-antigen vaccine for colorectal cancer. 2018 catalysts include full two-year survival data from the pancreatic cancer trial (Phase I/II) with TG01 and interim data readouts from the melanoma (Phase I) and mesothelioma (Phase Ib/II) trials with ONCOS-102. Our valuation is marginally higher at NOK1.78bn or NOK33.8/share.


Executive interview - Targovax

Edison TV: | Pharmaceutical & healthcare | 08 Nov 2017

In this short video Magnus Jaderberg, Chief Medical Officer of Targovax gives us some background on Targovax and discusses key technology areas.


Priming immune response in anticancer combos

Initiation | Pharmaceutical & healthcare | 08 Nov 2017

Targovax is an immuno-oncology (IO) company specialising in two distinct, but complementary approaches. ONCOS-102 is a genetically engineered adenovirus being tested in advanced melanoma, mesothelioma and three other indications run by partners. From the TG platform two mutant RAS-specific, neo-antigen cancer vaccines are in development for colorectal and pancreatic cancers, for which interim Phase I/II results with positive survival data were presented at ASCO in June 2017. Targovax’s core proposition is to use its products as immune response primers and combine with other anticancer therapies, such as checkpoint inhibitors, for increased efficacy. We value Targovax at NOK1.69bn or NOK32.1 per share.